A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction
Standard
A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction. / Kyhl, Kasper; Lønborg, Jacob; Vejlstrup, Niels; Kelbæk, Henning; Helqvist, Steffen; Holmvang, Lene; Jørgensen, Erik; Saunamäki, Kari; Bøtker, Hans Erik; Clemmensen, Peter; Køber, Lars; Treiman, Marek; Engstrøm, Thomas.
in: EUROINTERVENTION, Jahrgang 12, Nr. 4, 20.07.2016, S. 449-455.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction
AU - Kyhl, Kasper
AU - Lønborg, Jacob
AU - Vejlstrup, Niels
AU - Kelbæk, Henning
AU - Helqvist, Steffen
AU - Holmvang, Lene
AU - Jørgensen, Erik
AU - Saunamäki, Kari
AU - Bøtker, Hans Erik
AU - Clemmensen, Peter
AU - Køber, Lars
AU - Treiman, Marek
AU - Engstrøm, Thomas
PY - 2016/7/20
Y1 - 2016/7/20
N2 - AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.
AB - AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Electrocardiography/methods
KW - Exenatide
KW - Female
KW - Heart Failure/epidemiology
KW - Humans
KW - Male
KW - Middle Aged
KW - Myocardial Infarction/epidemiology
KW - Peptides/therapeutic use
KW - Percutaneous Coronary Intervention/methods
KW - Platelet Aggregation Inhibitors/therapeutic use
KW - Prognosis
KW - Treatment Outcome
KW - Venoms/therapeutic use
U2 - 10.4244/EIJV12I4A78
DO - 10.4244/EIJV12I4A78
M3 - SCORING: Journal article
C2 - 27436599
VL - 12
SP - 449
EP - 455
JO - EUROINTERVENTION
JF - EUROINTERVENTION
SN - 1774-024X
IS - 4
ER -